HER-2 positivity is a high risk of recurrence of stage I gastric cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The treatment of gastric cancer remains unsatisfactory. We aimed to investigate the prognostic value of immunohistochemical staining in gastric cancer. Methods: We analyzed 505 (279 early staged, 226 advanced-staged) gastric cancer tissues from patients who underwent radical gastric resection between January 2014 and December 2016. Available surgical specimens immunohistochemically stained for p53, epidermal growth factor receptor (EGFR), human EGFR 2 (HER-2), E-cadherin, and Ki-67 were reviewed. We evaluated the association between positivity to various biomarkers and disease recurrence, disease-free survival, lymph node metastasis, and microscopic lymphovascular invasion. Results: The median follow-up duration was 32.5 months (range, 7 to 70). Advanced gastric cancer cases showed high Ki-67 expression; other cases showed unremarkable expression. Concerning disease recurrence, lymphatic invasion, and disease-free interval, all biomarkers had no prognostic effects. HER-2-positive stage I gastric cancer tended to occur in old patients and in the upper one-third of the stomach (p = 0.01). HER-2 positivity was significantly correlated with disease recurrence (p = 0.01), lymphatic invasion (p = 0.03), and vascular invasion (p = 0.03) in stage I cases. Conclusions: Only HER-2 was associated with the recurrence of stage I gastric cancer. HER-2-positive stage I gastric cancer requires additional therapy despite curative resection.
Abstract
Background/Aims: The treatment of gastric cancer remains unsatisfactory. We aimed to investigate the prognostic value of immunohistochemical staining in gastric cancer. Methods: We analyzed 505 (279 early staged, 226 advanced-staged) gastric cancer tissues from patients who underwent radical gastric resection between January 2014 and December 2016. Available surgical specimens immunohistochemically stained for p53, epidermal growth factor receptor (EGFR), human EGFR 2 (HER-2), E-cadherin, and Ki-67 were reviewed. We evaluated the association between positivity to various biomarkers and disease recurrence, disease-free survival, lymph node metastasis, and microscopic lymphovascular invasion. Results: The median follow-up duration was 32.5 months (range, 7 to 70). Advanced gastric cancer cases showed high Ki-67 expression; other cases showed unremarkable expression. Concerning disease recurrence, lymphatic invasion, and disease-free interval, all biomarkers had no prognostic effects. HER-2-positive stage I gastric cancer tended to occur in old patients and in the upper one-third of the stomach (p = 0.01). HER-2 positivity was significantly correlated with disease recurrence (p = 0.01), lymphatic invasion (p = 0.03), and vascular invasion (p = 0.03) in stage I cases. Conclusions: Only HER-2 was associated with the recurrence of stage I gastric cancer. HER-2-positive stage I gastric cancer requires additional therapy despite curative resection.
참고문헌 (41)
- Mathers CD, "Global and regional estimates of cancer mortality and incidence by site: I. Application of regional cancer survival model to estimate cancer mortality distribution by site", BMC Cancer, 2, pp.36~ (2002)
- Karimi P, "Gastric cancer : descriptive epidemiology, risk factors, screening, and prevention", Cancer Epidemiol Biomarkers Prev, 23, pp.700~713 (2014)
- Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, 357, pp.1810~1820 (2007)
- Bang YJ, "Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC) : a phase 3 open-label, randomised controlled trial", Lancet, 379, pp.315~321 (2012)
- Correia M, "Basic aspects of gastric cancer", Helicobacter, 14(Suppl 1), pp.36~40 (2009)
- Marrelli D, "Prediction of recurrence after radical surgery for gastric cancer : a scoring system obtained from a prospective multicenter study", Ann Surg, 241, pp.247~255 (2005)
- Washington K., "7th Edition of the AJCC cancer staging manual: stomach", Ann Surg Oncol, 17, pp.3077~3079 (2010)
- Lazar D, "Ki-67 expression in gastric cancer : results from a prospective study with longterm follow-up", Rom J Morphol Embryol, 51, pp.655~661 (2010)
- Ko GH, "Prognostic impact of Ki-67in patients with gastric cancer: the importance of depth of invasion and histologic differentiation", Medicine (Baltimore), 96, pp.e7181~ (2017)
- Slamon DJ, "Human breast cancer : correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- Boku N, "HER2-positive gastric cancer", Gastric Cancer, 17, pp.1~12 (2014)
- Park DI, "HER-2", neu amplification is an independent prognostic factor in gastric cancer, 2006, pp.51, 1371~1379
- Ansari J, "The prognostic significance of Her2-neu over expression in gastric carcinomas", Iran J Cancer Prev, 4, pp.170~176 (2011)
- Kim JW, "The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen", Anticancer Res, 32, pp.1547~1553 (2012)
- Movagharnejad K, "HER-2", neu marker examination using immunohistochemical method in patients suffering from gastric adenocarcinoma, 2013, pp.2, 199~203
- Yonemura Y, "Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer", Cancer Res, 51, pp.1034~1038 (1991)
- Roh JK, "Overexpression of erbB-2 protein in gastric adenocarcinoma : a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen", Gan To Kagaku Ryoho, 19(8 Suppl), pp.1207~1219 (1992)
- Jorgensen JT, "HER2 as a prognostic marker in gastric cancer : a systematic analysis of data from the literature", J Cancer, 3, pp.137~144 (2012)
- Nagaraja V, "HER2 expression in gastric and oesophageal cancer : a meta-analytic review", J Gastrointest Oncol, 6, pp.143~154 (2015)
- Feizy A, "HER2 expression status and prognostic, diagnostic, and demographic properties of patients with gastric cancer : a single center cohort study from Iran", Asian Pac J Cancer Prev, 19, pp.1721~1725 (2018)
- Oono Y, "Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples", Gastric Cancer, 22, pp.335~343 (2019)
- Wang HB, "Clinicopathological factors associated with HER2-positive gastric cancer: a meta-analysis", Medicine (Baltimore), 96, pp.e8437~ (2017)
- Gravalos C, "HER2 in gastric cancer : a new prognostic factor and a novel therapeutic target", Ann Oncol, 19, pp.1523~1529 (2008)
- Jorgensen JT, "Targeted HER2 treatment in advanced gastric cancer", Oncology, 78, pp.26~33 (2010)
- Sano T, "Recurrence of early gastric cancer : follow-up of 1475 patients and review of the Japanese literature", Cancer, 72, pp.3174~3178 (1993)
- Amini N, "Clinicopathological features and prognosis of gastric cardia adenocarcinoma : a multi-institutional US study", J Surg Oncol, 111, pp.285~292 (2015)
- Okholm C, "Status and prognosis of lymph node metastasis in patients with cardia cancer : a systematic review", Surg Oncol, 23, pp.140~146 (2014)
- Herbst RS, "Review of epidermal growth factor receptor biology", Int J Radiat Oncol Biol Phys, 59(2 Suppl), pp.21~26 (2004)
- Paez JG, "EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Begnami MD, "Evaluation of cell cycle protein expression in gastric cancer : cyclin B1 expression and its prognostic implication", Hum Pathol, 41, pp.1120~1127 (2010)
- Pinto-de-Sousa J, "Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma", Histopathology, 44, pp.323~331 (2004)
- Ye YW, "The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients", J Surg Oncol, 106, pp.872~879 (2012)
- Yildirim M, "Prognostic significance of p53 in gastric cancer : a metaanalysis", Asian Pac J Cancer Prev, 16, pp.327~332 (2015)
- Wei K, "The prognostic significance of p53 expression in gastric cancer : a meta-analysis", J Cancer Res Clin Oncol, 141, pp.735~748 (2015)
- Chan AO, "E-cadherin in gastric cancer", World J Gastroenterol, 12, pp.199~203 (2006)
- Xing X, "The prognostic value of E-cadherin in gastric cancer : a meta-analysis", Int J Cancer, 132, pp.2589~2596 (2013)
- Czyzewska J, "The expression of E-cadherin-catenin complex in patients with advanced gastric cancer : role in formation of metastasis", Folia Histochem Cytobiol, 48, pp.37~45 (2010)
- Kawanishi K, "Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers", Am J Clin Pathol, 113, pp.266~274 (2000)
- Kakeji Y, "Predictive value of Ki-67 and argyrophilic nucleolar organizer region staining for lymph node metastasis in gastric cancer", Cancer Res, 51, pp.3503~3506 (1991)
- Boger C, "Ki67 : an unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity", J Surg Oncol, 113, pp.46~54 (2016)
- Huang G, "High Ki67 expression has prognostic value in surgically-resected T3 gastric adenocarcinoma", Clin Lab, 62, pp.141~153 (2016)